EdwardChanMD
Pediatric Hematology & Oncology • Thousand Oaks, CAClinical research medical director, Amgen
Dr. Chan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
One Amgen Center Drive
Bldg 27, 3E
Thousand Oaks, CA 91320
Summary
- Edward Chan, MD, is a pediatric hematologist/oncologist based in Thousand Oaks, CA. He earned his medical degree from Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo in 1997, then completed a pediatrics residency at University at Buffalo and a pediatric hematology/oncology fellowship at Cincinnati Children's Hospital Medical Center. He has held positions at Cincinnati Children's Hospital, Stony Brook University Hospital, and currently works as a Clinical Research Clinical Scientist at Amgen. His experience is in clinical research and pediatric hematology/oncology. He also has numerous publications under his belt, with the majority being in the area of oncology. Additionally, he has been involved in several clinical trials focusing on advanced non-CNS tumors, melanoma, and neuroblastoma.
Education & Training
Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Hematology/Oncology, 2000 - 2003
University at BuffaloResidency, Pediatrics, 1997 - 2000- Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1997
Certifications & Licensure
NY State Medical License 2005 - 2026- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
- Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma Start of enrollment: 2015 Feb 03
- Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma Start of enrollment: 2014 Dec 08
- Join now to see all
Publications & Presentations
PubMed
- 9 citationsDeregulation of the cell cycle by breast tumor kinase (Brk).Edward L. Chan, Anjaruwee S. Nimnual
International Journal of Cancer. 2010-12-01 - 3 citationsFavorable histology, MYCN-amplified 4S neonatal neuroblastomaEdward L. Chan, Richard E. Harris, Kathleen H. Emery, Michael J. Gelfand, Margaret H. Collins
Pediatric Blood & Cancer. 2007-04-01 - 52 citationsA novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis.S. Leah Etheridge, Megan E. Cosgrove, Veena Sangkhae, Lana M. Corbo, Michelle E. Roh
Blood. 2014-02-13
Grant Support
- Validating the prognostic value of EGFR768 in neuroblastomaNational Cancer Institute2014–2016
- Ron as an adjunct biomarker for EGFR expressing head and neck cancersAmerican Cancer Society2009–2015
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
